|
Systolic blood pressure (mmHg)
|
135.1 (15.2)
|
127.3 (8.7)
|
0.004
|
|
Diastolic blood pressure (mmHg)
|
78.8 (8.8)
|
78.1 (5.6)
|
0.110
|
|
BP < 130/80 mmHg (%)
|
132 (74.2)
|
163 (84.5)
|
0.045
|
|
Laboratory tests
| | | |
|
eGFR EPI-CKD (mL/min)
|
60.7 (22.9)
|
60.4 (22.5)
|
0.920
|
|
Albuminuria (mg/day)
|
90.2 (38–160)
|
54 (11–180)
|
0.179
|
|
Albuminuria < 30 mg/day (%)
|
18 (13.0)
|
62 (37.6)
|
0.047
|
|
Fasting plasma glucose (mg/dL)
|
153.6 (44.8)
|
147.4 (39.4)
|
0.199
|
|
HbA1c (%)
|
7.4 (1.1)
|
6.9 (0.6)
|
0.009
|
|
HbA1c < 7% (%)
|
88 (52.1)
|
129 (64.8)
|
0.133
|
|
Total cholesterol (mg/dL)
|
190.9 (33)
|
173 (28.9)
|
0.015
|
|
Total cholesterol < 175 mg/dL (%)
|
55 (32.5)
|
106 (53.2)
|
0.054
|
|
LDL cholesterol (mg/dL)
|
122.3 (29.8)
|
100.5 (26.5)
|
< 0.001
|
|
LDL < 100 mg/dL (%)
|
34 (20.1)
|
106 (53.2)
|
0.001
|
|
Triglycerides (mg/dL), median (IQR)
|
122 (90–171)
|
145 (120–169)
|
0.794
|
|
Therapy
| | | |
|
Anti-hypertensive drugs, median (IQR)
|
1 (1–3)
|
2 (1–3)
|
< 0.001
|
|
ACEi/ARBs, No. (%)
| | | |
|
ACEi
|
104 (61.8)
|
7 (3.4)
| |
|
ARBs
|
56 (33.1)
|
5 (2.3)
| |
|
ACE + ARBs
|
3 (1.8)
|
187 (94.3)
| |
|
None
|
6 (3.6)
|
–
|
< 0.001
|
|
Diuretics, No. (%)
|
84 (49.7)
|
113 (56.8)
|
0.864
|
|
Calcium channel Blockers, No. (%)
|
59 (34.9)
|
79 (39.7)
|
0.687
|
|
Beta-blockers, No. (%)
|
30 (17.8)
|
38 (19.1)
|
0.961
|
|
Alpha-blockers, No. (%)
|
6 (3.6)
|
10 (4.8)
|
0.574
|
|
Diabetes therapy, No. (%)
| | |
0.843
|
|
Diet
|
5 (2.9)
|
5 (2.5)
| |
|
Insulin
|
57 (33.7)
|
73 (36.7)
| |
|
Oral anti-hyperglycemics
|
77 (45.6)
|
88 (44.2)
| |
|
Combined therapy
|
16 (9.5)
|
25 (12.6)
| |
|
Missing
|
14 (8.3)
|
8 (4)
| |
|
Use of statins, No. (%)
|
84 (49.7)
|
110 (55.3)
|
0.991
|
|
Use of antiplatelets, No. (%)
|
104 (61.6)
|
148 (74.4)
|
0.905
|
